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Abstract. Currently the international development of veterinary transfusion medicine 
has an increasing tendency. The objectives of this study were to demonstrate the efficacy of 
blood products therapy and the low incidence of transfusion reactions. A number of 22 
patients (19 dogs and 3 cats) were included in this study during 2009 to 2011. These patients 
received blood component therapy (fresh whole blood-FWB, erythrocyte concentrate -EC or 
plasma) in the Emergency Hospital (Faculty of Veterinary Medicine-Cluj Napoca) and some 
private clinics, based on clinical and/or hematological parameters and they where monitored a 
variable period of time. The patients diagnosis were: hypovolemic shock, external or internal 
hemorrhage, parvovirosis or intussusception with clinically hemorrhagic gastro-enteritis, 
babesios, septic shock, acute renal failure, chronic renal failure, coagulopathy. Blood 
component therapy conducted to the clinical recovery of 45% patients. The posttransfusion 
increase of the basic blood parameters (erythrocytes number, hematocrit, hemoglobin) were 
statistically significant and support the efficacy of transfusion with FWB or EC. The cessation 
of small bleedings, in the first 24 hours after transfusion with FWB and plasma and restore of 
the bleeding and clotting time at the physiologic values in the next 24 hours, shows the 
efficacy of these blood products transfusion in coagulopathies with clinical manifestation. 
Transfusion therapy with compatible blood products appropriate to a specific disease in dogs 
and cats could be lifesaving in several emergency situations, especially when it is performed 
in time and is based on the corroboration of the clinical and hematological data of the patient. 
 




Transfusion medicine is a relatively new and rapidly growing area of research in 
Veterinary Medicine (Castellanos et al., 2004). Blood products transfusion is an important 
component in the therapeutic protocol of many diseases and it has specific indications. Whole 
blood is mainly indicated for fluid substitution in severe posthemorrhagic anaemia, due to 
accidents or surgical intervention with large blood loss. The erythrocyte concentrate (EC) is 
used in normovolemic patients, with immune mediated hemolytic anemia, inefficient 
erythropoesis or Babesiosis to support the oxygen transport to the tissue. Blood plasma is 
indicated in the treatment of acquired or inherited coagulation disorders, including those due 
to deficit of vitamin K dependent coagulation factors or of those consumed in disseminated 
intravascular coagulation (Chiaramonte D., 2004). 
Blood transfusion is considered a mild form of transplant, which first involves the 
investigation of compatibility between partners, provision of quality blood products and 
respectively their administration in a correct and aseptic manner.  
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MATERIALS AND METHODS 
 
In the period from 2009 to 2011, 22 patients (19 dogs and 3 cats) presented at the 
emergency hospital and clinics of the Faculty of Veterinary Medicine Cluj – Napoca, but also 
at some veterinary private practices received transfusions with blood products (whole blood 
transfusion, EC and plasma) and were included in this study. 
The patients diagnoses were: hypovolemic shock after external or internal 
hemorrhage, parvovirosis or intussusception with clinically hemorrhagic gastro-enteritis, 
Babesios, septic shock, acute renal failure, chronic renal failure, coagulopathy. Based on their 
clinical evaluation and hematologic parameters values of the patients, the current clinician 
recommended the administration of the appropriate blood product as a part of the therapeutic 
protocol. To perform the transfusions, the following materials were needed: blood products 
(FWB, EC and plasma), infusion sets, automatic injector, 50mls syringes, pulse-oximeter or 
monitor for supervision of vital functions, saline, hematology analyzer-Abacus Junior Vet, 
hemocytometers and Hayem liquid. 
The decision to transfuse 5 dogs and a cat was based on their clinical status, the 
emergency situation and the available materials, while in 14 dogs and two cats, it was made a 
corroboration of the clinical and paraclinical parameters. 
The most patients (n=21) received whole blood from the collection bags through an 
administration set and small dogs or cats (1,5-10kg) from 20 or 50 mls syringes through 
intravenous catheters (20-24G). The EC was administrated in a single case, from the 
collection bag after a prior dilution with saline (3:1). Using a 50mls syringe, plasma was 
collected from the blood bag after a passive sedimentation and two patients were treated with 
this product by an automatic injector. Almost all patients received a single dose of FWB or 
EC (20 mL-450 mL), except two dogs: one with two FWB transfusions 2 days apart and the 
other with a plasma transfusion at the second day after a FWB transfusion. 
The compatibility tests were held before the administration of the blood products. 
The clinical intra-transfusion status of the patients was monitored during therapy for 
early detection of the possible transfusion reactions. Monitoring parameters included 
measurements of temperature, heart rate, pulse strength and synchronicity, mucous 
membranes and respiratory rate, 3 times in the first 30 minutes and each half hour to the end 
of the procedure. The patients were carefully observed if vomiting, tachycardia, dyspnoea, 
diarrhea, salivation, angioedema, urticaria, facial oedema or hemoglobinuria had developed 
during transfusion. 
Post-transfusion monitoring of the patients (between a day to two weeks) depended on 
the severity of diagnosis, the number of transfusions and the individual post-therapeutic 
evolution. Before and after transfusion (48h), hematology analysis were performed and the 
obtained data were processed and analyzed statistically using the GraphPad InStat (Unpaired t 
test). 
 
RESULTS AND DISCUSSIONS 
 
In a group of 22 patients the introduction of blood products transfusion in their 
therapeutic protocol was the base for the clinical recovery of 45 % of them (9 dogs and a cat). 
Most patients (55 %) had severe clinical course ended with the death or euthanasia: 3 cases 
died during transfusion and 9 cases at various time after transfusion (24h to 7 days).  
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Transfusion of FWB, EC or plasma did not cause fatal adverse reactions during the 
administration (maximum 4h) but some of them developed mild tachycardia and a transient 
state of agitation, probably due to a painful reaction at the site of administration. 
The immediate beneficial effects of the therapy with blood products (the first 24 hours 
post-transfusion) consisted in the general improvement of the most patients by the end of 
administration. The pale mucous color, initially white because anemia and inadequate oxygen 
delivery, became normal (light pink or pink as appropriate), thereby reducing the mortality 
and morbidity. Among post-transfusion reactions, at 24-48 hours, hyperthermia (40
0
C) was 
noted in two dogs. Most patients under clinical supervision up to 7 days, showed steady 
improvement of the general condition, the physiologic restoration of the basic hematologic 
parameters and 10 of them were clinically recovered. 
The specific disease and the prognostic played an important role in the clinical post-
transfusion evolution; thereby the individual analysis presented differences among patients. In 
this regard, in dogs diagnosed with coagulopathy (a dog with anticoagulant rodenticide 
intoxication and two dogs with suspicion of disseminated intravascular coagulopathy -DIC) 
the micro-hemorrhages stopped ( epistaxis, bleeding to the site of lesion) in the first 24 hours 
and the coagulation time became normal after 48 hours in two cases, only one needed an 
additional plasma transfusion. For one of these patients the owners decided euthanasia. 
Cases with anemia of different etiology had a favorable post-transfusion clinical 
evolution, confirmed by the normalization of the main hematological parameters.  
In dogs the comparison of the data before and after transfusion revealed increases of 









/l), from 6,33 g/dl hemoglobin (2,7-12,3 g/dl) to 11,31 g/dl hemoglobin 
(5,8-17 g/dl) and from 17,93% (8,5-32,8) to 31,28% (22,18-44,97) for the hematocrit. (fig1, 2, 
3). The statistical analysis of these data showed the fact that the two-tailed P values (0.0013, 
0.0055 and 0.0039 respectively) was considered very significant. 
The administered average of the therapeutic dose was 10 ml/kg FWB, 5 ml/kg plasma 
and 2,5 ml/kg EC in one case.  
 













Fig.1. Post-transfusion evolution of the average erythrocytes number 
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Fig. 2 Post-transfusion evolution of the average hemoglobin value 
 














Fig. 3 Post-transfusion evolution of the average hematocrit value  
 
Concerning transfusion decision in cats, the ante-transfusion hemoglobin (average-
2,65 g/dl) and hematocrit values (average-8,7%) represented an important element. 
At the deceased patients there was not found any incompatibility before transfusion  
and there was no post-transfusion reaction, thereby, the cause of death was not attributed to 
blood component administration. 
Blood transfusion therapy in dogs and cats experienced a considerable expansion in 
recent years, including in our country, becoming an important component in different 
therapeutic protocols, with much lower risk of adverse reactions due to availability of 
compatibility tests. 
The analysis of the obtained data requires their integration into the general clinical 
context of the patients, that underwent blood component therapy (FWB, whole blood, EC or 
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plasma), which usually have an unfavorable prognosis, being in critical state, with severe 
evolutions. 
Using blood transfusion as therapy we consider that we obtained an appreciable 
percentage of survival (45%), which must be correlated with the severity of the syndromes in 
question. These results along with a higher survival percent of transfused patients (80%) 
reported by Ognean et al. (2010), encourages the process of blood component therapy in our 
area. In this study blood transfusion was more indicated in anemic conditions (81%), caused 
by hemorrhages, hemolysis, inefficient erythropoiesis, immune mediated hemolytic anemia or 
neoplasm. Although in the case of one anemic patient with acute or chronic evolution, it is 
appropriate to administer FWB or EC, but to avoid circulatory overload, especially in a 
patient with cardiopathy in chronic evolution the wisest choose is EC (Cotter SM, 1991, 
Pisciotto PT, 1993). In the case of one feline patient (female in the last stage of gestation) 
with hemolytic anemia (probably due to Haemobartonella felis infection), FWB was the best 
choice, because the young age of the transfused erythrocytes was important. This cat had a 
positive evolution and later she was sterilized and subjected to specific antibiotic therapy. The 
oldest erythrocytes from a donor blood are the most susceptible to hemolysis (Smith JE, 1991; 
Cotter SM, 1991). Therefore a unit of WB fresher than 5 days contains a higher percentage of 
young red blood cells, which will have better chance to survive hemolysis. Thus, in patients 
with immune mediated hemolytic anemia is recommended the transfusion of FWB stored up 
to 5 days, increasing in this way the beneficial effects of transfusion (Cotter SM, 1991, Miller 
E and Green M, 1994), because the transfused red blood cells will be destroyed in the same 
rate like the patient own cells (Smith JE, 1991). 
A cat from this study, with nonregenerative anemia (suspected of bone marrow 
neoplasm) received FWB as it is indicated, with a higher percentage of young red blood cells 
which prolong the life and viability of transfusion. (Smith JE, 1991). Even if the anemia is 
very severe in cats and the hematocrit under 15%, some studies reports that recovery 
percentage can achieve 84 % (Weingart et al. 2004) 
The post-transfusion target values for the hematocrit are 25-35% in dogs and 20-25% 
in cats (Kerwin, S.C. and G.E., Mauldin 2003). These values were achieved according to our 
obtained data: the post-transfusion hematocrit average of 32,33% in dogs and 20% in cats. 
Based on the investigation results of the haemostatic system in 3 dogs, which showed 
the prolongation of the bleeding and coagulation time in association with clinical signs 
(wound bleeding, lung rales and epistaxis) the whole blood and plasma transfusion was 
decided. In this situation the products used by us are indicated to provide red blood cells and 
labile or stable clotting factors (Cotter SM, 1991, Pisciotto PT, 1993, Kerwin, S.C. and G.E., 
Mauldin, 2003). Two of these dogs recovered spectacular, but the 3rd, a dog with a very 
serious prognostic couldn’t be saved for economic reasons, because he required further 
plasma transfusions even if he had an encouraging transient clinical posttransfusion evolution. 
Fresh plasma, used in a dog with DIC suspicion, also has several indications, such as 
von Willebrand disease, congenital coagulopathy as hemophylia A or severe warfarin 
intoxication, because contains the stable vitamin K factors (II,VII, IX, X) and FV, VIII and 
vWF (Meyers KM and Wardrop KJ, 1991, Cotter SM, 1991). 
 A single plasma administration usually stops bleeding and rapidly improves the 
prolonged clotting times (Hohenhaus, A. E. 2006). Thereby at an hour after transfusion the 
efficacy could be evaluated by testing the clotting time (Kerwin, S.C. and G.E., Mauldin, 
2003).  
In a quarter of patients (24 %) the decision of transfusion relied exclusively on clinical 
signs, because the emergency situations or high costs for owners. The clinical signs indicating 
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to transfuse a patient appear when the hematocrit in dangerously low. In humans exertional 
dyspnea occurs when the hemoglobin concentration falls to less then 7 g/dL. When the value 
is less then 6 g/dL some patients experienced tachycardia, hypotension and impaired 
consciousness, but for animals there are few available data. Therefore, relying on clinical 
signs of anemia to guide transfusion decision probably results in significant under-transfusion 
of patients. Moreover, relying on clinical signs in anesthetized animal obviously is fruitless. 
Healthy animals subjected to acute hemodilution, tolerate hemoglobin levels between 3 and 5 
g/dL. When Hb is less than 3 g/dL, ischemic electrocardiograph, increased lactate production, 
depressed ventricular function and death occur (Wingfield, W. E., 2001). In this context, the 
patients transfused exclusively based on clinical signs, were already in a very critical status, 
evidenced by a increased rate of mortality (86%). 
Blood typing and Crossmatch reduce considerably the risk of severe hemolytic 
reactions, but still can occur acute hypersensitive and allergic reactions, to thrombocytes and 
leucocytes and therefore their rapid recognition and treatment is essential (Kerwin, S.C. and 
G.E., Mauldin, 2003). The febrile reaction in two transfused dogs was probably due to the 
transfused leucocytes, but it was transient and the treatment with antithermics was effective. 
If blood administration is performed too fast can cause hypersalivation, emesis and 
muscular fasciculation (Brown D. and Vap L., 2004), as it happened in one dog strongly 
unbalanced hidro-electrlytic at the 2nd blood transfusion, after the 2nd enterectomy. 
In patients with circulatory overload, tachypnea, dyspnea or tachycardia occurred, but 
in such cases, slowing or stopping the blood product administration resulted in restoration of 
heart and respiratory rate and the transfusion could be continued in a slower rate. 
The clinical recovered patients didn’t show delayed transfusion reaction, such as 
delayed hemolysis, immunosupression, purpura or graft versus host disease. These reactions 
cannot be prevented by blood typing or Crossmatch-ing (Hohenhaus, A.E., 2006) 
Delayed hemolysis can be revealed by the unexpected decrease of the hematocrit at 
two days to 2 weeks after transfusion and appear most frequently in dogs that received before 
a transfusion, with a low titer of antibodies undetected by Crossmatch. In this situation the 
hemoglobinemia and hemoglobinuria doesn’t appear, but because of extra vascular hemolysis, 




 Following the introduction of WB, EC or plasma transfusion in the therapeutically 
protocol in a group of 22 dogs and cats, with critical status (anemia and coagulopathy with 
different etiology), conducted to the clinical recovery of 45% patients. 
 The posttransfusion increase of the basic blood parameters (erythrocyte number, 
hematocrit, hemoglobin) were statistically very significant and support the efficacy of 
transfusion with WB or EC. 
 The cessation of the micro hemorrhage, in the first 24 hours after transfusion with FWB 
and plasma, with the restore of bleeding and clotting time at the physiologic values in 
another 24 hours, shows the efficacy of these blood products transfusions in 
coagulopathies with clinical manifestation. 
 Transfusion therapy with compatible blood products, appropriate to a specific disease in 
dogs and cats could be lifesaving in several emergency situations, especially when it is 
performed in time and is based on the corroboration of the clinical and hematological data 
of the patient. 
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